SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001682873-19-000001
Filing Date
2019-01-03
Accepted
2019-01-03 13:05:04
Documents
1
Period of Report
2018-12-19

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primary_doc.html 4  
1 PRIMARY DOCUMENT primary_doc.xml 4 2998
  Complete submission text file 0001682873-19-000001.txt   4381
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Issuer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address 9900 CAVENDISH BLVD ST LAURENT A8 H4M 2V2
Business Address
Danielsen Erik (Reporting) CIK: 0001682873 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-12033 | Film No.: 19504509